Igm Biosciences Inc (IGMS) Stock Price, Quote & News

Company Profile

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 650 965 7873

Website: igmbio.com

Address:

325 East Middlefield Road, Mountain View, United States

SmartContent Jun. 2 at 8:30 AM

$IGMS halted its lead autoimmunity programs after weak trial results and cut over 70% of its workforce, but it still holds $184M in cash vs. a $76M market cap, giving it significant optionality to reboot its oncology pipeline. The market is discounting the firm below cash value, making this a deep-value biotech play with high risk but huge upside if it redeploys capital effectively.

0 · Reply

scrit May. 29 at 5:21 PM

$IGMS why this volume spike?

0 · Reply

scrit May. 28 at 3:23 PM

$IGMS maybe I’m an idiot buying 40.000 shares, but I smell a buyout. Market cap well below cash, we just need a powerful company to take over. I hope I’m not gambling too much…🙈

0 · Reply

JB_Research May. 27 at 8:25 PM

$IGMS Straight from their latest 10-Q: " After the termination of the Sanofi Agreement, we are not currently developing any product candidates..." "Our strategic alternatives focus on our potential internal research and development opportunities, a merger, sale, other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of our assets ... The market capitalization of our company is below current cash value and investments. Consequently, any potential counterparty may choose not to spend the additional resources necessary to continue developing our product candidates and may attribute little or no value..." https://investor.igmbio.com/node/10721/html

1 · Reply

Ali100_A May. 10 at 12:27 AM

$IGMS Is it known why Sanofi axed the entire IgM deal? Is it because IgM are too complicated to express and the fact that they are massive in size being 5 times the size of a IgG antibody.

0 · Reply

EquityInvest May. 5 at 5:07 AM

$IGMS heard that they will be filing for bankruptcy soon it was only a matter of time ha ha

0 · Reply

ret0258 Apr. 22 at 6:13 PM

$IGMS

0 · Reply

EquityInvest Apr. 3 at 5:58 PM

$VXRT $IGMS $VXRT $AMPH $SLRN go back to all my posts on these companies over the last few years and see the returns that I am talking about shorting. These are companies that all could and should go bankrupt. Click to subscribe!

0 · Reply

EquityInvest Apr. 3 at 5:55 PM

$IGMS I was so sure this was going to zero and I’m kicking myself for stopping my short a few months ago. At this point it’s dead money so I guess I’ll move on but look forward to dellisting

0 · Reply

PepCF Mar. 24 at 6:05 PM

$IGMS baker bross 6'89% 🤔

0 · Reply

IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out

Jan 9, 2025, 1:00 PM EST - 5 months ago

IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

Nov 8, 2024, 7:00 AM EST - 8 months ago

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 7:00 AM EST - 8 months ago

IGM Biosciences to Present at Three Upcoming Investor Conferences

Oct 1, 2024, 11:41 AM EDT - 9 months ago

IGM Biosciences' stock tumbles as analysts weigh in on pivot plan with dismay

Oct 1, 2024, 11:40 AM EDT - 9 months ago

IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO

Oct 1, 2024, 8:00 AM EDT - 9 months ago

IGM Biosciences Stock Drops 27% on ‘Pipeline Transformation' to Autoimmune Diseases

Oct 1, 2024, 7:54 AM EDT - 9 months ago

IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Sep 30, 2024, 4:01 PM EDT - 9 months ago

IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

Sep 10, 2024, 4:05 PM EDT - 10 months ago

IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit

Aug 14, 2024, 7:00 AM EDT - 11 months ago

IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update

May 29, 2024, 7:00 AM EDT - 1 year ago

IGM Biosciences to Present at the Jefferies Healthcare Conference

May 8, 2024, 4:10 PM EDT - 1 year ago

IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 7:00 AM EDT - 1 year ago

IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference

Apr 17, 2024, 8:30 AM EDT - 1 year ago

IGM Biosciences Announces Refocusing of Sanofi Collaboration

Apr 10, 2024, 7:00 AM EDT - 1 year ago

IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Mar 7, 2024, 4:10 PM EST - 1 year ago

IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 12, 2024, 3:09 PM EST - 1 year ago

IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points

Feb 1, 2024, 7:00 AM EST - 1 year ago

IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 3, 2024, 7:00 AM EST - 1 year ago

IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 6, 2023, 2:44 AM EST - 1 year ago

Medivir to present at the Carlsquare Equity Research Investor Day

Dec 5, 2023, 4:01 PM EST - 1 year ago

IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension

Dec 1, 2023, 5:32 AM EST - 1 year ago

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Nov 27, 2023, 3:52 AM EST - 1 year ago

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

Nov 22, 2023, 2:46 AM EST - 1 year ago

Medivir to present at the Redeye Life Science Day

Nov 21, 2023, 2:48 AM EST - 1 year ago

Medivir to present at the Erik Penser Bank Company Event

Nov 13, 2023, 4:10 PM EST - 1 year ago

IGM Biosciences Announces Third Quarter 2023 Financial Results

Nov 13, 2023, 3:49 AM EST - 1 year ago

Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA

Nov 7, 2023, 7:00 AM EST - 1 year ago

IGM Biosciences to Present at Two Upcoming Investor Conferences

Oct 25, 2023, 2:46 AM EDT - 1 year ago

Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

Oct 23, 2023, 2:48 AM EDT - 1 year ago

Nomination Committee of Medivir appointed

Oct 20, 2023, 9:29 AM EDT - 1 year ago

Change in Medivir's Board of Directors

Oct 5, 2023, 7:29 AM EDT - 1 year ago

Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles

Oct 3, 2023, 4:05 PM EDT - 1 year ago

IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z.

Sep 11, 2023, 5:41 AM EDT - 1 year ago

Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study

Sep 7, 2023, 3:46 AM EDT - 1 year ago

Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA

Sep 6, 2023, 7:00 AM EDT - 1 year ago

IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 4, 2023, 2:52 AM EDT - 1 year ago

Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima

Sep 1, 2023, 3:20 AM EDT - 1 year ago

Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC

Aug 14, 2023, 3:03 AM EDT - 2 years ago

Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included

Aug 7, 2023, 2:46 AM EDT - 2 years ago

Medivir partners with world-leading liver cancer experts in new Scientific Advisory Council

Aug 3, 2023, 4:10 PM EDT - 2 years ago

IGM Biosciences Announces Second Quarter 2023 Financial Results

Jul 3, 2023, 4:01 PM EDT - 2 years ago

IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jun 22, 2023, 7:58 AM EDT - 2 years ago

IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement

Jun 21, 2023, 5:17 PM EDT - 2 years ago

IGM Announces Proposed Public Offering and Concurrent Private Placement

Jun 19, 2023, 4:12 AM EDT - 2 years ago

Medivir's patent application for fostrox approved in China

Jun 2, 2023, 5:30 PM EDT - 2 years ago

IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

Jun 2, 2023, 3:22 AM EDT - 2 years ago

Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima

SmartContent Jun. 2 at 8:30 AM

0 · Reply

scrit May. 29 at 5:21 PM

$IGMS why this volume spike?

0 · Reply

scrit May. 28 at 3:23 PM

$IGMS maybe I’m an idiot buying 40.000 shares, but I smell a buyout. Market cap well below cash, we just need a powerful company to take over. I hope I’m not gambling too much…🙈

0 · Reply

JB_Research May. 27 at 8:25 PM

1 · Reply

Ali100_A May. 10 at 12:27 AM

$IGMS Is it known why Sanofi axed the entire IgM deal? Is it because IgM are too complicated to express and the fact that they are massive in size being 5 times the size of a IgG antibody.

0 · Reply

EquityInvest May. 5 at 5:07 AM

$IGMS heard that they will be filing for bankruptcy soon it was only a matter of time ha ha

0 · Reply

ret0258 Apr. 22 at 6:13 PM

$IGMS

0 · Reply

EquityInvest Apr. 3 at 5:58 PM

0 · Reply

EquityInvest Apr. 3 at 5:55 PM

$IGMS I was so sure this was going to zero and I’m kicking myself for stopping my short a few months ago. At this point it’s dead money so I guess I’ll move on but look forward to dellisting

0 · Reply

PepCF Mar. 24 at 6:05 PM

$IGMS baker bross 6'89% 🤔

0 · Reply

NVDAMillionaire Mar. 21 at 12:49 PM

$IGMS Pivot looks rough. Autoimmune strategy feels like a Hail Mary after Sanofi oncology termination. Cash runway good but development halt on key candidates signals deeper issues. Watching closely for strategic alternatives. interesting article: https://beyondspx.com/article/igm-biosciences-inc-igms-a-biotech-in-flux-as-it-pivots-from-cancer-to-autoimmune-diseases

0 · Reply

PenkeTrading Mar. 19 at 9:32 AM

I found you an Oversold RSI (Relative Strength Index) on the daily chart of IGM Biosciences Inc. Is that bullish or bearish? $IGMS #RsiOversold #NASDAQ

0 · Reply

EquityInvest Mar. 3 at 5:30 PM

$IGMS short to zero!!! Follow my method. Fund crap CEOs in pharma and watch them destroy wealth. Check out $AMPH for another example

0 · Reply

EquityInvest Feb. 18 at 7:32 PM

$IGMS dead money!!!! CEO sucks!! 😂😂

1 · Reply

Jlloyd31 Feb. 12 at 2:51 PM

$IGMS Long some here, 1.32 avg. See if volume comes in and we get a bounce on the daily. Oversold Name

0 · Reply

PenkeTrading Feb. 12 at 6:29 AM

I found you a RSI Bullish Reversal Divergence on the daily chart of IGM Biosciences Inc. $IGMS #BullishReversalDivergence #NASDAQ

0 · Reply

EquityInvest Jan. 31 at 9:13 PM

$IGMS anybody left here? 😂 should have listened to me when it was at 70!!!! CEO does not understand science. Check his records. He is a scammer!!!!

0 · Reply

AZOZ Jan. 28 at 2:47 PM

$IGMS Oversold swing idea 💡

1 · Reply

Wrenboy Jan. 25 at 8:13 PM

$IGMS 😉👇

0 · Reply

TheLearnerEarner Jan. 22 at 4:01 PM

$IGMS ✅ BARGAIN stock swing trade - healthcare - small cap - 4/9 F-Score - 3.3x relative volume - 12x analysts coverage - revenue is forecast to grow per year - short term gains (with potential for a medium term upgrade) 💱 RSI: 19.33 (oversold heavily) 📊⚓ Analysts Price Target: $5.00 - $22.00 (192% - 1171% above Price) 🌟 Range (12m) $1.59 - $22.50 💰 NEWSDESK (last recent article) 📰 https://www.stocktitan.net/news/IGMS/igm-biosciences-provides-strategic-update-on-autoimmunity-pipeline-uo1b2d45v6sq.html

0 · Reply

30DeltaSpy Jan. 22 at 2:46 PM

$IGMS bullish 💰💃

0 · Reply

Vladimirputncalls Jan. 15 at 10:32 PM

$IGMS This has double written all over it. Mark this post. For Rome.

1 · Reply

Market Cap	69.94M
Revenue (ttm)	2.68M
Net Income (ttm)	-195.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,305.97%
Debt to Equity Ratio	0.00

Volume	149,700
Avg Vol	179,774
Day's Range	N/A - N/A
Shares Out	59.78M
Stochastic %K	14%
Beta	0.52
Analysts	Hold
Price Target	$1.70